Cessation of long-acting beta 2-agonist in children with persistent asthma on inhaled corticosteroids

International guidelines recommend adding long-acting beta 2-agonists (LABA) to inhaled corticosteroids (ICS) as a step 3 or 4 strategy in children in whom ICS, with or without adjunct therapy, is ineffective in adequately controlling asthma [1-4]. Contrary to adults, the beneficial effects of ICS/L...

Full description

Saved in:
Bibliographic Details
Published inThe European respiratory journal Vol. 48; no. 2; pp. 558 - 560
Main Authors Ducharme, Francine M, Gagnon, Roxanne, Benard, Brigitte, Tse, Sze Man, Thivierge, Robert
Format Journal Article
LanguageEnglish
Published 26.08.2016
Online AccessGet full text

Cover

More Information
Summary:International guidelines recommend adding long-acting beta 2-agonists (LABA) to inhaled corticosteroids (ICS) as a step 3 or 4 strategy in children in whom ICS, with or without adjunct therapy, is ineffective in adequately controlling asthma [1-4]. Contrary to adults, the beneficial effects of ICS/LABA in children are limited to improving lung function and short-acting beta 2-agonist use (SABA), with no significant reduction in symptoms compared with ICS alone [5]; moreover, a nonsignificant trend towards more exacerbations requiring oral corticosteroids and/or hospital admissions raised concerns [5]. Asthma-related intubations and deaths linked to LABA [6] have led the US Food and Drug Administration to issue label changes recommending that LABA is discontinued once asthma control has been achieved [7].
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
ISSN:0903-1936
DOI:10.1183/13993003.00014-2016